Revolution Medicines reiterates $2.1B-$2.2B 2026 GAAP operating expense guidance following RASONQUE launchNov 4, 8:48 PM ET#RVMD
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate ProgressNov 4, 4:04 PM ET#RVMD